By Karla L. Palmer – As announced in the Federal Register on June 3, 2015, FDA is proposing to deschedule [123I]Ioflupane (ioflupane) from Schedule II of the Controlled Substances Act (CSA). Ioflupane is an active pharmaceutical ingredient and new molecular entity in DaTscan, which is a …
Menu